Healthcare provider profile · identity verified

Richard J Granger, MD

Internal Medicine · EVERETT, WA · NPI 1760421085

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	541	170
Amlodipine Besylate	Amlodipine Besylate	302	97
Lisinopril	Lisinopril	255	87
Levothyroxine Sodium	Levothyroxine Sodium	237	68
Losartan Potassium	Losartan Potassium	225	74
Gabapentin	Gabapentin	209	57
Tamsulosin Hcl	Tamsulosin Hcl	200	61
Omeprazole	Omeprazole	184	64
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	169	32
Metoprolol Succinate	Metoprolol Succinate	147	43
Oxycodone Hcl	Oxycodone Hcl	127	25
Simvastatin	Simvastatin	126	33
Metformin Hcl	Metformin Hcl	113	40
Trazodone Hcl	Trazodone Hcl	98	36
Sertraline Hcl	Sertraline Hcl	97	33
Metformin Hcl Er	Metformin Hcl	96	37
Metoprolol Tartrate	Metoprolol Tartrate	95	29
Furosemide	Furosemide	94	37
Albuterol Sulfate Hfa	Albuterol Sulfate	83	36
Pantoprazole Sodium	Pantoprazole Sodium	82	29
Jardiance	Empagliflozin	81	18
Rosuvastatin Calcium	Rosuvastatin Calcium	80	27
Meloxicam	Meloxicam	78	24
Hydrochlorothiazide	Hydrochlorothiazide	76	28
Allopurinol	Allopurinol	73	22
Duloxetine Hcl	Duloxetine Hcl	70	20
Clopidogrel	Clopidogrel Bisulfate	60	19
Atenolol	Atenolol	54	21
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	53	11
Donepezil Hcl	Donepezil Hcl	49	11
Pregabalin	Pregabalin	48	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	42	suppressed
Fluticasone Propionate	Fluticasone Propionate	42	19
Famotidine	Famotidine	40	suppressed
Potassium Chloride	Potassium Chloride	38	16
Triamcinolone Acetonide	Triamcinolone Acetonide	38	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	13
Finasteride	Finasteride	36	16
Humulin N	Insulin Nph Human Isophane	36	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	36	13
Humalog Kwikpen U-100	Insulin Lispro	35	12
Carvedilol	Carvedilol	34	11
Lorazepam	Lorazepam	34	suppressed
Mirtazapine	Mirtazapine	34	11
Pravastatin Sodium	Pravastatin Sodium	34	11
Acyclovir	Acyclovir	32	suppressed
Morphine Sulfate Er	Morphine Sulfate	32	suppressed
Buspirone Hcl	Buspirone Hcl	31	suppressed
Ondansetron Odt	Ondansetron	31	11
Oxycontin	Oxycodone Hcl	31	suppressed
Spironolactone	Spironolactone	31	12
Alendronate Sodium	Alendronate Sodium	29	14
Chlorthalidone	Chlorthalidone	29	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	28	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Tramadol Hcl	Tramadol Hcl	27	suppressed
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Alvesco	Ciclesonide	25	12
Shingrix	Varicella-Zoster Ge/As01b/Pf	24	22
Baclofen	Baclofen	23	suppressed
Methenamine Hippurate	Methenamine Hippurate	23	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	22	suppressed
Spiriva Respimat	Tiotropium Bromide	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Glipizide	Glipizide	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Ozempic	Semaglutide	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Digoxin	Digoxin	19	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Ketoconazole	Ketoconazole	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Glimepiride	Glimepiride	18	suppressed
Topiramate	Topiramate	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Ursodiol	Ursodiol	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	14	suppressed
Torsemide	Torsemide	14	suppressed
Fentanyl	Fentanyl	13	suppressed
Morphine Sulfate	Morphine Sulfate	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Phenobarbital	Phenobarbital	13	suppressed
Dextroamphetamine Sulfate	Dextroamphetamine Sulfate	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Oxcarbazepine	Oxcarbazepine	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	11	11
Olanzapine	Olanzapine	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error